Code Biotherapeutics, Inc., (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announced its upsized and oversubscribed Series A financing...
Pharmaceutical giant Bristol Myers Squibb Company announced a $4.1 billion deal for Turning Point Therapeutics Inc on Friday morning, the first sizable acquisition for...
Targeting cosmetics brands, the London-based biotech startup has scooped up a $6.2 million seed round to prove it can scale its petroleum-free, compostable packaging,...
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and...